Drugs / NaBen®
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02261519 | Mar 2017 → Nov 2023 | schizophrenia | SyneuRx International (Taiwan) Corp | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT01908192 | Jun 2014 → Oct 2023 | schizophrenia | SyneuRx International (Taiwan) Corp | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT03094429 Comparator | Mar 2017 → Sep 2026 overdue | schizophrenia | SyneuRx International (Taiwan) Corp | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-03-18 | SyneuRx International (Taiwan) Corp | Results The Study of Ω-NaBen, a Novel Crystalline Form of Sodium Benzoate, has been published in CNS & Neurological Disorders – Drug Targets, indicating its Superior Physicochemical Properties, Central Nervous System Effects, and Antipsychotic Activities. syneurx.com ↗
A recent study by SyneuRx has revealed superior pharmaceutical properties of Ω(omega)-NaBen, a novel crystalline form of sodium benzoate (NaBen). |
| 2021-03-09 | SyneuRx International (Taiwan) Corp | Regulatory TFDA Approves SyneuRx’s Schizophrenia Trials in Taiwan as part of its Global Schizophrenia Trials syneurx.com ↗ |
| 2021-03-09 | SyneuRx International (Taiwan) Corp | Regulatory 心悅生醫兩項治療精神分裂症新藥獲台灣衛福部核准執行 第二(b)/三期人體臨床試驗 syneurx.com ↗
2021年3月8日，心悅生醫宣布研發中的難治型精神分裂症合併治療新藥ClozaBen®(SND12)，以及成人精神分裂症加成治療新藥NaBen®(SND13)，獲台灣衛福部核准執行第二(b)/三期人體臨床試驗。 |
| 2021-02-28 | SyneuRx International (Taiwan) Corp | Results 心悅生醫發表Ω苯甲酸鈉之研究成果 syneurx.com ↗
而我們的研究發現Ω晶型之苯甲酸鈉因為具有更佳的物化特性以及生物利用度，較其他晶型之苯甲酸鈉更為優越、更具潛力成為新一代更具療效的創新中樞神經疾病藥物。 |
All press releases naming this drug 7 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NaBen | “The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).” NCT01908192 ↗ |
| Action | Inhibit | “NaBen® (DAAO Inhibitor)” NCT02261519 ↗ |
| Route | Oral | “NaBen® is a white oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.” NCT01908192 ↗ |